國藥現代(600420.SH):“注射用艾司奧美拉唑鈉”獲批上市
格隆匯2月17日丨國藥現代(600420.SH)公佈,近日,公司全資子公司國藥集團容生製藥有限公司(“國藥容生”)收到國家藥品監督管理局核准簽發的“注射用艾司奧美拉唑鈉”藥品註冊證書。
注射用艾司奧美拉唑鈉可作為當口服療法不適用時胃食管反流病的替代療法,用於降低成人胃和十二指腸潰瘍出血內鏡治療後再出血風險,預防重症患者應激性潰瘍出血。
注射用艾司奧美拉唑鈉由阿斯利康製藥公司(AstraZeneca AB)研製開發,2003年率先在瑞典上市,2007年在中國批准上市。CDE網站顯示,目前該藥品國內主要生產企業有正大天晴藥業集團股份有限公司、遼寧海思科製藥有限公司、江蘇奧賽康藥業有限公司等。根據米內網數據庫顯示,2021年注射用奧美拉唑鈉國內城市公立醫院終端銷售額約人民幣39.51億元。
截至目前,該項目累計投入研發費用約人民幣300萬元(未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.